Evidence map›Paper›PMID 34368077›Full record

ArticleFrontiers in chemistry2021

Synthetic Integrin-Targeting Dextran-Fc Hybrids Efficiently Inhibit Tumor Proliferation

Hendrik Schneider, Simon Englert, Arturo Macarrón Palacios, Jorge Alberto Lerma Romero, Ataurehman Ali, Olga Avrutina, Harald Kolmar

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hendrik SchneiderInstitute for Organic Chemistry and Biochemistry, Technical University Darmstadt, Darmstadt, Germany.
Simon EnglertInstitute for Organic Chemistry and Biochemistry, Technical University Darmstadt, Darmstadt, Germany.
Arturo Macarrón PalaciosInstitute for Organic Chemistry and Biochemistry, Technical University Darmstadt, Darmstadt, Germany.
Jorge Alberto Lerma RomeroInstitute for Organic Chemistry and Biochemistry, Technical University Darmstadt, Darmstadt, Germany.
Ataurehman AliInstitute for Organic Chemistry and Biochemistry, Technical University Darmstadt, Darmstadt, Germany.
Olga AvrutinaInstitute for Organic Chemistry and Biochemistry, Technical University Darmstadt, Darmstadt, Germany.
Harald KolmarInstitute for Organic Chemistry and Biochemistry, Technical University Darmstadt, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we present the design, synthesis, and biological evaluation of novel integrin-targeting molecular hybrids combining RGD peptides and a potent cytotoxin presented on dextran polysaccharides. Based on an aglycosylated Fc as a centerpiece, endosomal-cleavable cytotoxic agent monomethyl auristatin E (MMAE) and dextran as multimerization site were covalently connected by two bioorthogonal enzyme-mediated reactions site-specifically. Decoration of dextran with cyclic RGD peptides, introduced by copper "click" reaction, resulted in the final constructs with the potential to kill integrin-overexpressing tumor cells. We found that these modifications had little impact on the stability of the Fc scaffold and the RGD-bearing construct showed good binding properties of αvβ3-expressing U87MG cells. Furthermore, the construct showed a remarkable antiproliferative activity. These results demonstrate the general capability of our design to provoke receptor-mediated endocytosis upon binding to the cellular surface, followed by endosomal cleavage of the linkage between Fc-dextran and MMAE and its subsequent release. Our approach opens new avenues to transcribe small molecule binders into tailor-made multimeric molecular hybrids with antitumor potential.

Indexed as

dextrandrug delivery and targetingintegrinsmultimerizationRGD peptide

Identifiers

PMID34368077
PMCPMC8339797
OpenAlexW3186636267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.